
Molecular Neurodegeneration
@molneuro
The #1 ranked open-access neuroscience peer-reviewed journal with a 2023 Impact Factor (IF) of 15.1 and a 5-year IF of 16.8. Official journal of @_BrightFocus
ID: 229487985
http://molecularneurodegeneration.biomedcentral.com 22-12-2010 14:44:57
1,1K Tweet
2,2K Followers
688 Following


'Mechanisms of interventions targeting modifiable factors for #dementia risk reduction' Anna Matton, Ruth Stephen, Makrina Daniilidou ...Miia Kivipelto Miia Kivipelto Karolinska Institutet …arneurodegeneration.biomedcentral.com/articles/10.11…



🚨 Big news! 🚨 Our 2024 Impact Factor is 17.5 🎉 We're now ranked #4 out of 314 neuroscience journals and proudly remain the #1 open-access, peer-reviewed journal in neuroscience 🧠✨ A huge thank you to our editors, authors, BrightFocus Foundation and readers for their support!


We're proud to share that Molecular Neurodegeneration (MN), the official scientific journal of BrightFocus Foundation, has reached an impact factor of 17.5—a 17% increase over the previous year’s impact factor of 14.9! 🎉 Molecular Neurodegeneration has been the #1 open-access neuroscience



'Alpha-#synuclein seeding amplification assays in #Lewybodydementia: a brief review' Maria Bregendahl, Zeynep Bengisu Kaya, Wolfgang Singer, Pamela J. McLean Mayo Clinic Neuro #synucleinopathies #biomarker …arneurodegeneration.biomedcentral.com/articles/10.11…


'Current strategies in the management of #dementia with #lewybodies and future directions based on disease pathophysiology' Daniel Erskine & John-Paul Taylor John-Paul Taylor Newcastle University …arneurodegeneration.biomedcentral.com/articles/10.11…



Methylome analysis of #FTLD patients with #TDP43 pathology identifies #epigenetic signatures specific to pathological subtypes Cristina T. Vicente, Tejasvi Niranjan, Elise Coopman...Rosa Rademakers VIB Center for Molecular Neurology Mayo Clinic Neuro …arneurodegeneration.biomedcentral.com/articles/10.11…



'#Biomarkers and therapeutic strategies targeting microglia in #neurodegenerative diseases: current status and future directions' Min-Young Noh, Hyuk Sung Kwon, Min-Soo Kwon, Minyeop Nahm...Seung Hyun Kim Hanyang Univ. #microglia …arneurodegeneration.biomedcentral.com/articles/10.11…


'#Proteomic landscape of #AlzheimersDisease: emerging technologies, advances and insights (2021 – 2025)' Jay M. Yarbro, Him K. Shrestha...Junmin Peng Junmin Peng Structural Biology at St. Jude Children's Hospital @StjudeResearch …arneurodegeneration.biomedcentral.com/articles/10.11…




We are thrilled that Dr Pete Williams of Karolinska Institute will be our next webinar speaker! From bench to bedside and back again: Targeting NAD for neuroprotection in #glaucoma Aug 11, 2025 10-11am ET Host: Dr Diane Bovenkamp BrightFocus Foundation Register: bit.ly/4o6WrqY


'Glycerophospholipids in #ALS: insights into disease mechanisms and clinical implication' Thibaut Burg Thibaut Burg & Ludo Van Den Bosch Ludo Van Den Bosch #LipidMetabolism Leuven Brain Institute KU Leuven …arneurodegeneration.biomedcentral.com/articles/10.11…


'The role of #endolysosomal #progranulin and #TMEM106B in neurodegenerative diseases' Hideyuki Takahashi & Stephen M. Strittmatter Yale School of Medicine …arneurodegeneration.biomedcentral.com/articles/10.11…


Excited to share my last publication with Ludo Van Den Bosch published in Molecular Neurodegeneration. Our review explores emerging evidence on how disruptions in glycerophospholipid metabolism contribute to ALS pathogenesis. #ALS #motorneuron #lipidmetabolism …arneurodegeneration.biomedcentral.com/articles/10.11…